Search results for "trials"

showing 10 items of 966 documents

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospecti…

2008

SUMMARY Pegylated interferon with ribavirin (Peg/R) is the most effective therapy for chronic hepatitis C virus (HCV) but its utility and effectiveness after liver transplantation has been difficult to assess. We evaluated efficacy, tolerability, and safety of Peg/R in liver transplant candidates and recipients with HCV cirrhosis. We searched medical databases and conference proceedings between January 1999 and January 2008 selecting randomized and nonrandomized studies. Primary end points meta-analytically were: (1) sustained viral response (SVR) and (2) histological response. Secondary end points were: (1) treatment discontinuation, (2) mortality, and (3) rejection episodes. Pegylated int…

Liver Cirrhosismedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepacivirusPharmacologyLiver transplantationAntiviral AgentsGastroenterologyPolyethylene Glycolschemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesRandomized Controlled Trials as TopicClinical Trials as Topiccirrhosis HCV pegylated interferon ribavirin transplantation.Hepatologybusiness.industryRibavirinvirus diseasesmedicine.diseaseHepatitis CLiver TransplantationDiscontinuationTransplantationRegimenTreatment OutcomeInfectious DiseaseschemistryTolerabilityDrug Therapy CombinationInterferonsbusinessmedicine.drug
researchProduct

Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update.

2020

Background: Lifestyle interventions aimed at weight loss have been associated with improved liver enzymes, reduced intrahepatic triglyceride content, and improved histology (including reduced fibrosis stage). Objective: To revise the evidence on the beneficial effects of lifestyle changes accumulated since 2015, following the publication of the pivotal Cuban experience with histologic outcome. Methods: A PubMed search covering the period 2015 to July 2019 was carried out. All retrieved references were analyzed and double-checked by authors. Results: 20 new studies were identified; in addition, two relevant studies provided new evidence. Thirteen studies were classified as randomized, contr…

Liver Cirrhosismedicine.medical_specialtyFibrosiLiver CirrhosiPopulationMotivational interviewingInformation technology01 natural sciencesTriglycerideElectronic mail03 medical and health sciencesWeight lossFood intakeNon-alcoholic Fatty Liver DiseaseDrug DiscoveryNonalcoholic fatty liver diseaseWeight LossmedicineHumanseducationLife StyleTriglycerides030304 developmental biologyRandomized Controlled Trials as TopicPharmacology0303 health scienceseducation.field_of_studyInternetText MessagingCirrhosiElectronic Mailbusiness.industrymedicine.diseasePhysical activity steatosiWeight Lo0104 chemical sciencesTelephone010404 medicinal & biomolecular chemistryObservational Studies as TopicBehavior therapyCohortPhysical therapyObservational Studies as TopicObservational studymedicine.symptomBehavior therapy Cirrhosis Fibrosis Food intake Information technology Physical activity steatosisbusinessHumanCurrent pharmaceutical design
researchProduct

Bupivacaine 0.5% versus articaine 4% for the removal of lower third molars. A crossover randomized controlled trial.

2012

Objective: To compare the anesthetic action of 0.5% bupivacaine in relation to 4% articaine, both with 1:200,000 epinephrine, in the surgical removal of lower third molars. As a secondary objective hemodynamic changes using both anesthetics were analyzed. Study Design: Triple-blind crossover randomized clinical trial. Eighteen patients underwent bilateral removal of impacted lower third molars using 0.5% bupivacaine or 4% articaine in two different appointments. Preoperative, intraoperative and postoperative variables were recorded. Differences were assessed with McNemar tests and repeated measures ANOVA tests. Results: Both solutions exhibited similar latency times and intraoperative effic…

Local anesthesiaAdultMalemedicine.medical_specialtyAnestèsia en odontologiaAdolescentHemodynamicsCarticaineArticainelaw.inventionPostoperative painYoung AdultDolor postoperatoriClinical trialsRandomized controlled trialDouble-Blind MethodlawMedicineTeeth extractionHumansAnesthetics LocalGeneral DentistryExtracció dentalBupivacaineCross-Over Studiesbusiness.industryRepeated measures designAnestèsia localDent molar:CIENCIAS MÉDICAS [UNESCO]Crossover studyMolarBupivacaineSurgeryBlood pressureOtorhinolaryngologyAnesthesiaAnestheticUNESCO::CIENCIAS MÉDICASTooth ExtractionSurgeryFemaleMolar ThirdResearch-ArticleAnesthesia in dentistryOral Surgerybusinessmedicine.drugAssaigs clínicsMedicina oral, patologia oral y cirugia bucal
researchProduct

Anesthetic efficacy of Oraqix versus Hurricaine and placebo for pain control during non-surgical periodontal treatment

2014

Objectives: To evaluate the efficacy of Oraqix® during scaling and root planing (SRP) in comparison with 20% benzocaine and placebo. Study Design: 15 patients requiring 4 sessions of SRP were enrolled. For each patient, Oraqix®, Hurricaine®, vaseline or no anesthetic product were randomly assigned each to a quadrant. Treatment pain was evaluated on a 100 mm Visual Analog Scale (VAS) and on a Verbal Rating Scale (VRS). The amount of product administered, the need to re-anesthetise, patient and operator satisfaction and the onset of side-effects were also recorded. Results: Oraqix® was significantly better than nothing, with a reduction of VAS score to 13.3 units, but without significant diff…

Local anesthesiaMaleLidocaineBenzocaineRoot PlaningClinical trialsScaling and root planingPain treatmentAnesthesiaPeriodontologyAnesthetics LocalAnestèsia localMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludBenzocaineTreatment OutcomeAnesthesiaUNESCO::CIENCIAS MÉDICASFemaleAnesthesia in dentistryPeriodontal diseasemedicine.drugAdultAnestèsia en odontologiamedicine.medical_specialtyVisual analogue scaleOdontologíaMalalties periodontalsPlaceboPrilocaineVaselineTractament del dolorDouble-Blind MethodmedicineHumansPain ManagementLidocaine Prilocaine Drug CombinationGeneral DentistryAgedbusiness.industryResearchLidocainePrilocaineSurgeryOtorhinolaryngologyAnestheticDental ScalingSurgerybusinessAssaigs clínicsMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Evidence on the effects of exercise therapy in the treatment of chronic disease

2009

Evidence on the effects of exercise in the treatment of patients with chronic diseases should be based on well designed randomised controlled trials. The most consistent finding of the meta-analyses summarised in the present work is that aerobic/functional capacity and muscle strength can be improved by exercise training among patients with different diseases without having detrimental effects on disease progression. This is important, as with population aging exercise therapy may be an important means of reducing disability and increasing the number of older people living independently. Additionally, there is accumulating evidence that in patients with chronic disease exercise therapy is e…

Lung Diseasesmedicine.medical_specialtyPhysical Therapy Sports Therapy and RehabilitationType 2 diabetesOsteoarthritisMeta-Analysis as TopicDiabetes mellitusmedicineHumansOrthopedics and Sports MedicineIn patientMusculoskeletal DiseasesRisk factorIntensive care medicineRandomized Controlled Trials as TopicEvidence-Based Medicinebusiness.industryExercise therapyGeneral MedicineEvidence-based medicinemedicine.diseaseExercise TherapyChronic diseaseDiabetes Mellitus Type 2Cardiovascular DiseasesChronic DiseasePhysical therapyNervous System DiseasesbusinessBritish Journal of Sports Medicine
researchProduct

The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target?

2014

Abstract: The advent of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represented the most important innovation in NSCLC treatment over the last years. However, despite a great initial activity, secondary mutations in the same target, or different alterations in other molecular pathways, inevitably occur, leading to the emergence of acquired resistance, in median within the first year of treatment. In this scenario, the mesenchymal-epidermal transition (cMET) tyrosine kinase receptor and its natural ligand, the hepatocyte growth factor (HGF), seem to play an important role. Indeed either the overexpression or the amplification of cMET, as well as the overexpr…

Lung NeoplasmscMETcMET; cMET-Inhibitors; EGFR-TKIs resistance; HGF; NSCLC; Targeted therapies; Molecular Medicine; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistryClinical BiochemistryAntineoplastic AgentsBiologyPharmacologyNSCLCReceptor tyrosine kinaseTargeted therapiesCarcinoma Non-Small-Cell LungDrug DiscoverymedicineHumansEpidermal growth factor receptorHGFLung cancerProtein Kinase InhibitorsEGFR inhibitorsEGFR-TKIs resistancePharmacologyClinical Trials as TopicPharmacology. TherapyDrug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalProto-Oncogene Proteins c-metmedicine.diseaseMolecular medicinerespiratory tract diseasesErbB ReceptorsDrug Resistance NeoplasmProto-Oncogene Proteins c-metbiology.proteinCancer researchMolecular MedicineDrug Therapy CombinationHepatocyte growth factorcMET-InhibitorTargeted therapiecMET-InhibitorsTyrosine kinasemedicine.drug
researchProduct

Low-level laser therapy in patients with Burning Mouth Syndrome : a double-blind, randomized, controlled clinical trial

2019

Background Evaluate the effect of LLLT in the treatment of burning mouth syndrome (BMS). Material and methods Twenty-one BMS patients were randomly assigned to two groups: 12 in the laser group (LG) and 9 in the control group (CG). Patients in the LG underwent 2-week sessions of LLLT for 4 weeks. The spot tip area of this tool is 0.088cm2, semi-conductor GaAlAs, with a wavelength of 808nm ±5nm (infrared), 200 mW output power, 1.97W/cm2 of power density, 3 J energy per point and application time 15 seconds per point. LLLT was applied punctually, in continuous emissions, on each of the sites where there was a symptom. Symptoms were evaluated with a visual analogue scale (VAS) and patient psyc…

Làsers en odontologiaVisual analogue scalemedicine.medical_treatment030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineClinical trialsmedicineIn patientGeneral DentistryLow level laser therapyUnivariate analysisOral Medicine and Pathologybusiness.industryResearch030206 dentistryBurning mouth syndrome:CIENCIAS MÉDICAS [UNESCO]DysgeusiaClinical trialEstudi de casosLasers in dentistryAnesthesiaUNESCO::CIENCIAS MÉDICASAnalysis of varianceCase studiesmedicine.symptombusinessAssaigs clínics
researchProduct

Emerging drugs for the treatment of vitiligo.

2020

Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treat…

MAP Kinase Signaling SystemAdministration TopicalVitiligoAdministration OralVitiligoBiologicsBioinformatics030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineClinical Trials Phase II as TopicLocalized vitiligoMedicineHumansJanus Kinase InhibitorsPharmacology (medical)skin and connective tissue diseasesRandomized Controlled Trials as TopicPharmacologytreatmentintegumentary systembusiness.industrymedicine.diseaseCombined Modality TherapyJAK inhibitorchemistryClinical Trials Phase III as Topic030220 oncology & carcinogenesisCytokinesAfamelanotideDermatologic AgentsbusinessJanus kinaseBiologics; JAK inhibitor; treatment; vitiligoExpert opinion on emerging drugs
researchProduct

Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy

2013

Abstract Recombinant erythropoietin (EPO) analogs [erythropoiesis-stimulating agents (ESA)] are clinically used to treat anemia in patients with cancer receiving chemotherapy. After clinical trials reporting increased adverse events and/or reduced survival in ESA-treated patients, concerns have been raised about the potential role of ESAs in promoting tumor progression, possibly through tumor cell stimulation. However, evidence is lacking on the ability of EPO to directly affect cancer stem–like cells, which are thought to be responsible for tumor progression and relapse. We found that breast cancer stem–like cells (BCSC) isolated from patient tumors express the EPO receptor and respond to …

MAPK/ERK pathwayOncologyCancer Researchmedicine.medical_treatmentFluorescent Antibody TechniqueApoptosisMice SCIDImmunoenzyme TechniquesMiceCell MovementMice Inbred NODhemic and lymphatic diseasesTumor Cells CulturedCulturedBlottingAnemiaFlow CytometryTumor CellsTRIALSOncologyDisease ProgressionNeoplastic Stem CellsFemaleWesternSignal Transductionmedicine.drugSTIMULATING AGENTSEXPRESSIONmedicine.medical_specialtyBlotting WesternAntineoplastic AgentsBreast NeoplasmsSCIDRECOMBINANT-HUMAN-ERYTHROPOIETIN STIMULATING AGENTS EXPRESSION MORTALITY TRIALS ANEMIA ALPHA ALDH1Breast cancerIn vivoInternal medicinemedicineAnimalsHumansBreast cancer Cancer stem cellsALDH1ErythropoietinProtein kinase BCell ProliferationSettore MED/04 - Patologia GeneraleChemotherapybusiness.industryMORTALITYCancerRECOMBINANT-HUMAN-ERYTHROPOIETINmedicine.diseaseALPHAErythropoietinTumor progressionInbred NODAnemia; Animals; Antineoplastic Agents; Apoptosis; Blotting Western; Breast Neoplasms; Cell Movement; Cell Proliferation; Disease Progression; Erythropoietin; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice Inbred NOD; Mice SCID; Neoplastic Stem Cells; Signal Transduction; Tumor Cells Cultured; Cancer Research; Oncologybusiness
researchProduct

Exercise treatment effect modifiers in persistent low back pain: an individual participant data meta-analysis of 3514 participants from 27 randomised…

2020

BackgroundLow back pain is one of the leading causes of disability worldwide. Exercise therapy is widely recommended to treat persistent non-specific low back pain. While evidence suggests exercise is, on average, moderately effective, there remains uncertainty about which individuals might benefit the most from exercise.MethodsIn parallel with a Cochrane review update, we requested individual participant data (IPD) from high-quality randomised clinical trials of adults with our two primary outcomes of interest, pain and functional limitations, and calculated global recovery. We compiled a master data set including baseline participant characteristics, exercise and comparison characteristic…

MINIMAL INTERVENTIONMOTOR CONTROL EXERCISESMedical and Health SciencesBody Mass Index0302 clinical medicineEngineeringGRADED ACTIVITYOrthopedics and Sports MedicineMass index030212 general & internal medicineRandomized Controlled Trials as TopicGENERAL EXERCISEexercise rehabilitationPATIENT-LEVELGeneral MedicineLow back painPeer reviewExercise TherapyMeta-analysis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingmedicine.symptommedicine.medical_specialtyExercise treatmentPhysical Therapy Sports Therapy and Rehabilitationintervention effectivenessFUNCTION-CENTERED REHABILITATIONCLINICAL-TRIALEducationHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciencesRC925SDG 3 - Good Health and Well-beingmedicineHumansFLEXION-DISTRACTIONProtocol (science)business.industryIndividual participant dataChronic Low Back Pain IPD Meta-Analysis GroupECOLOGICAL BIASSYSTEMATIC REVIEWSClinical trialmeta-analysislower backPhysical therapybusinessLow Back Pain030217 neurology & neurosurgerySport Sciences
researchProduct